leisure time -WSS

leisure time

author：hotspot 2025-09-30 00:38:15 - browse：2

Are there still too many biotech companies? How do you know when you’re in a bubble? And is there a wrong way to pronounce “TIGIT”?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Josh Schimmer and Eric Schmidt, two longtime analysts teaming up at Cantor Fitzgerald, join us for a back-to-school conversation as biotech enters the busy back third of 2023. We also discuss the latest news in the life sciences, including some scientific evolution at Biogen, new leadership at Illumina, and the future of CRISPR medicine.

For more on what we cover, here’s the news from Biogen; here’s more on Illumina; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Phenylephrine and the overlooked value of the placebo effect

WSS

FDA panel signals lack of confidence in Amgen cancer drug data

SEC charges former device maker CEO with $41 million fraud

When women are denied an abortion, their children fare worse than peers

A virus, fished out of a lake, may have saved a man’s life

Carvykti CAR

Why health care costs have stayed mostly flat since 2010

explore

leisure time

Wikipedia

Virginia high school admissions case could be legal follow

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Sana to lay off nearly a third of staff, de

In age of alternative facts, a scholarly course on calling out crap

SEC charges former device maker CEO with $41 million fraud

After affirmative action ruling, medical educators look to 'holistic review'

AI can decode, harness the power of the humane immune system

Affirmative action in medical school literally saved lives

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

entertainment

Medicare drug price negotiation hasn't dried up venture capital

3 questions for the future of Biden's cancer moonshot

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

VC firm General Catalyst wants to buy a health system

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

explore

hotspot

hotspot

leisure time